Hear from two authors of an ACCC/LUNGevity Foundation study that identified key areas of clinician need related to biomarker testing in NSCLC.
While the identification of actionable biomarkers is fueling huge advancements in precision medicine and targeted therapies for the management of non-small cell lung cancer (NSCLC), access to these tests and associated therapies are not consistent throughout the healthcare system and have the potential to worsen existing health disparities.
Hear from two authors of an ACCC/LUNGevity Foundation study that identified key areas of clinician need related to biomarker testing in NSCLC, including increased guideline familiarity, practical applications of guideline-concordant testing, enhancing patient-clinician discussions and education, and access to appropriate clinical trials.
Guests:
Christopher S. Lathan, MD, MS, MPH
Chief Clinical Access and Equity Officer, Dana-Farber Cancer Institute;
Associate Medical Director, Dana-Farber at St. Elizabeth’s Medical Center;
Assistant Professor of Medicine, Harvard Medical School
Nikki Martin
Director of Precision Medicine Initiatives
LUNGevity Foundation
“Lung cancer has a lot of opportunities for treatment that impacts patients’ quality of life–even in the metastatic setting. If we don’t get the appropriate treatment to the appropriate patient, all these great [molecular] improvements that we’re making will continue to worsen disparities and equity.” - Christopher S. Lathan, MD, MS, MPH
This podcast is produced as part of the “Eliminating Precision Medicine Disparities” education program. Funding & support provided by Genentech, Janssen, Merck & Co., and Foundation Medicine.
